Dr. Ischiropoulos's research objectives are to develop and test novel therapeutics for long-chain fatty acid oxidation (LCFA) disorders, a collection of inherited metabolic diseases that affect the heart, liver and muscle. A second area of interest is the resolution of the nitric oxide signaling pathways at the proteome level in the cardiovascular and neuronal systems.

Along with his colleagues, one of the current projects in Dr. Ischiropoulos’s lab involves synthesizing multifunctional hybrid molecules as potential therapeutics for LCFA oxidation disorders. He tests these molecules in fibroblasts from patients with mutations in carnitine palmitoyltransferase-2, very long chain acyl CoA dehydrogenase, and mitochondrial trifunctional protein.

He uses mass spectrometry-based proteomic technologies to identify and quantify the full spectrum of nitric oxide-induced post-translational modifications in the cardiovascular system, providing for the first time a system-level appreciation of nitric oxide signalling.

BS, Wagner College (Chemistry), 1984

PhD, New York Medical College (Experimental Pathology), 1990

Gisela and Dennis Alter Research Professor in Pediatric Neonatology

Research Professor of Pediatrics and Systems Pharmacology and Translational Therapeutics

Parker B. Francis Fellowship in Pulmonary Research, 1993-1996

Young Investigator Award, International Society for Free Radical Research, 1994

Young Investigator Award, Oxygen Society, 1995

Established Investigator, American Heart Association, 1996-2001

Academic Prize in Medicine, Bodossaki Foundation, Athens, Greece, 1998